KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Gross Profit (2016 - 2025)

Abbott Laboratories' Gross Profit history spans 17 years, with the latest figure at $6.5 billion for Q4 2025.

  • For Q4 2025, Gross Profit rose 8.37% year-over-year to $6.5 billion; the TTM value through Dec 2025 reached $25.0 billion, up 7.59%, while the annual FY2025 figure was $25.0 billion, 7.59% up from the prior year.
  • Gross Profit for Q4 2025 was $6.5 billion at Abbott Laboratories, up from $6.3 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $6.9 billion in Q1 2022 and bottomed at $5.3 billion in Q2 2021.
  • The 5-year median for Gross Profit is $5.9 billion (2024), against an average of $6.0 billion.
  • The largest annual shift saw Gross Profit surged 36.22% in 2021 before it dropped 21.6% in 2023.
  • A 5-year view of Gross Profit shows it stood at $6.7 billion in 2021, then dropped by 17.96% to $5.5 billion in 2022, then increased by 3.4% to $5.7 billion in 2023, then rose by 6.1% to $6.0 billion in 2024, then grew by 8.37% to $6.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Gross Profit are $6.5 billion (Q4 2025), $6.3 billion (Q3 2025), and $6.3 billion (Q2 2025).